Blueprint Medicines (BPMC) Stock Forecast & Price Target

$112.19

-1.50 (-1.32%)

(As of 07/26/2024 ET)

Blueprint Medicines - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 16 Analyst Ratings

Based on 16 Wall Street analysts who have issued ratings for Blueprint Medicines in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 5 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for BPMC.

Consensus Price Target

$116.33
3.69% Upside

High Forecast	$168.00
Average Forecast	$116.33
Low Forecast	$75.00

According to the 16 analysts' twelve-month price targets for Blueprint Medicines, the average price target is $116.33. The highest price target for BPMC is $168.00, while the lowest price target for BPMC is $75.00. The average price target represents a forecasted upside of 3.69% from the current price of $112.19.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$116.33	$108.00	$91.57	$75.94
Forecasted Upside	3.69% Upside	13.72% Upside	17.84% Upside	41.83% Upside

Get Blueprint Medicines Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto Swap Profits

625,000% Gain

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

BPMC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BPMC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Blueprint Medicines Stock vs. The Competition

Type	Blueprint Medicines	Medical Companies	S&P 500
Consensus Rating Score	2.63	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	3.69% Upside	3,123.40% Upside	9.09% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/12/2024	Morgan Stanley 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$110.00 ➝ $115.00	-3.04%
7/8/2024	Oppenheimer 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$114.00 ➝ $125.00	+11.91%
6/28/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$130.00 ➝ $130.00	+19.79%
6/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$125.00 ➝ $125.00	+19.90%
5/14/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$140.00	+29.57%
5/6/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
Get the Latest News and Ratings for BPMC and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.
5/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$121.00 ➝ $168.00	+57.78%
5/6/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$50.00 ➝ $97.00	-9.51%
5/3/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$65.00 ➝ $76.00	-29.10%
5/3/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $135.00	+25.94%
5/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $75.00	-30.70%
5/3/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$78.00 ➝ $104.00	-5.98%
4/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$120.00 ➝ $130.00	+40.00%
4/26/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$110.00 ➝ $110.00	+17.51%
12/22/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$85.00 ➝ $100.00	+16.37%
12/19/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$86.00 ➝ $115.00	+31.26%
6/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$48.00 ➝ $43.00	-26.14%
5/23/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$78.00 ➝ $82.00	+45.78%
5/5/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
11/2/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eun Yang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$84.00 ➝ $80.00	+65.84%
9/14/2022	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+27.23%
9/7/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$80.00 ➝ $90.00	+27.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:48 AM ET.

BPMC Forecast - Frequently Asked Questions

What is Blueprint Medicines' forecast for 2024?: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Blueprint Medicines is $116.33, with a high forecast of $168.00 and a low forecast of $75.00.
Should I buy or sell Blueprint Medicines stock right now?: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There is currently 1 sell rating, 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BPMC shares.
Does Blueprint Medicines's stock price have much upside?: According to analysts, Blueprint Medicines's stock has a predicted upside of 12.00% based on their 12-month stock forecasts.
Has Blueprint Medicines been upgraded by Wall Street analysts recently?: Over the previous 90 days, Blueprint Medicines's stock had 2 upgrades by analysts.
What analysts cover Blueprint Medicines?: Blueprint Medicines has been rated by research analysts at Barclays, Citigroup, HC Wainwright, JMP Securities, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Stephens, SVB Leerink, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Blueprint Medicines more than its competitors?: Analysts like Blueprint Medicines less than other "medical" companies. The consensus rating score for Blueprint Medicines is 2.63 while the average consensus rating score for "medical" companies is 2.72. Learn more on how BPMC compares to other companies.